SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $98.62, a high estimate of $110.00, and a low estimate of $90.00. Witnessing a positive shift, the current ...
Q24, but Q4 previews and FY2025 projections signal growth potential. Click for my updated look at HROW stock prospects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback